Raven MS - CalciMedica, Common Chief Officer
| CALC Stock | 2.78 0.03 1.07% |
Executive
Raven MS is Chief Officer of CalciMedica, Common Stock
| Address | 505 Coast Boulevard South, La Jolla, CA, United States, 92037 |
| Phone | 858-952-5500 |
| Web | https://www.calcimedica.com |
CalciMedica, Common Management Efficiency
The company has return on total asset (ROA) of (0.6492) % which means that it has lost $0.6492 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8376) %, meaning that it created substantial loss on money invested by shareholders. CalciMedica, Common's management efficiency ratios could be used to measure how well CalciMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.68. In addition to that, Return On Capital Employed is expected to decline to -2.82. As of December 18, 2024, Total Assets is expected to decline to about 11.6 M. In addition to that, Non Current Assets Total is expected to decline to about 551 KSimilar Executives
| Found 11 records | EXECUTIVE Age | ||
| David Liu | Protagonist Therapeutics | 74 | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Scott MD | Protagonist Therapeutics | N/A | |
| Abha Bommireddi | Protagonist Therapeutics | N/A | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Matthew JD | Protagonist Therapeutics | 53 | |
| Carter King | Protagonist Therapeutics | 53 | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| FACP MD | Protagonist Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.65 |
CalciMedica, Common Stock Leadership Team
Elected by the shareholders, the CalciMedica, Common's board of directors comprises two types of representatives: CalciMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CalciMedica,. The board's role is to monitor CalciMedica, Common's management team and ensure that shareholders' interests are well served. CalciMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CalciMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Stauderman, CoFounder Officer | ||
| Michael MBA, President COO | ||
| Rachel Leheny, CEO Director | ||
| Eric Roberts, Chief Board | ||
| John JD, General Counsel | ||
| Raven MS, Chief Officer | ||
| Stefan MD, CoFounder Advisor | ||
| Cindy Reiedenberg, Accountant | ||
| Daniel MBA, Interim Officer | ||
| Patrick Hogan, CoFounder Advisor | ||
| Sudarshan MD, Chief Officer | ||
| Anjana Rao, CoFounder Advisor | ||
| MBA MBA, President COO |
CalciMedica, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CalciMedica, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 17.09 M | ||||
| Shares Outstanding | 13.48 M | ||||
| Shares Owned By Insiders | 17.48 % | ||||
| Shares Owned By Institutions | 43.86 % | ||||
| Number Of Shares Shorted | 45.16 K | ||||
| Price To Book | 4.08 X | ||||
| EBITDA | (34.19 M) | ||||
| Net Income | (34.36 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CalciMedica, Common Stock offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CalciMedica, Common's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calcimedica, Common Stock Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calcimedica, Common Stock Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CalciMedica, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CalciMedica, Common. If investors know CalciMedica, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CalciMedica, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.11) | Return On Assets (0.65) | Return On Equity (0.84) |
The market value of CalciMedica, Common Stock is measured differently than its book value, which is the value of CalciMedica, that is recorded on the company's balance sheet. Investors also form their own opinion of CalciMedica, Common's value that differs from its market value or its book value, called intrinsic value, which is CalciMedica, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CalciMedica, Common's market value can be influenced by many factors that don't directly affect CalciMedica, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CalciMedica, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if CalciMedica, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CalciMedica, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.